Skip to main content
GDU LC 2023 Main banner

Full Schedule

  1. Home
  2. Full Schedule

Full Schedule

  • Thursday, September 21, 2023
  • 8:00 AM – 8:15 AM ET
    Welcome
  • 8:15 AM – 9:00 AM ET
    Session 1: Birdseye View of the Current Tretatment Landscape in Metastatic NSCLC without Actionable Mutations
  • 9:00 AM – 9:45 AM ET
    Session 2: Sensitizing and Atypical EGFR Mutations

    Presenter: Gregory J. Riely, MD, PhD – Memorial Sloan Kettering Cancer Center

  • 9:45 AM – 9:50 AM ET
    Exhibit Hall
  • 9:50 AM – 10:50 AM ET
    Non-CME Innovation Theater
  • 10:50 AM – 11:00 AM ET
    Exhibit Hall
  • 11:00 AM – 11:45 AM ET
    Session 3: EGFR: The Challenge of Primary and Secondary Resistance
  • 11:45 AM – 12:00 PM ET
    Session 4: Debate: Alectinib vs Lorlatinib in ALK Positive
  • 12:00 PM – 12:15 PM ET
    Session 4: Debate: Alectinib vs Lorlatinib in ALK Positive
  • 12:15 PM – 12:30 PM ET
    Session 4: Debate: Alectinib vs Lorlatinib in ALK Positive
  • 12:30 PM – 12:35 PM ET
    Exhibit Hall
  • 12:35 PM – 1:35 PM ET
    Non-CME Innovation Theater
  • 1:35 PM – 2:20 PM ET
    Session 5: Special Topic – Unique Immune Combinations with CPIs
  • 2:20 PM – 3:05 PM ET
    Session 6: Advancing the Management of NSCLC: A Focus on Emerging Therapies
  • 3:05 PM – 3:35 PM ET
    Exhibit Hall
  • 3:35 PM – 4:20 PM ET
    Session 7: The Era of ADCs in the Treatment of NSCLC Part 1: Class Overview and Specifics of TROP2, HER3, c-MET, and CEACAM5 Investigational ADCs
  • 4:20 PM – 5:05 PM ET
    Session 8: HER2 and the Emerging Roles of HER Family ADCs
  • Friday, September 22, 2023
  • 8:00 AM – 8:15 AM ET
    Welcome
  • 8:15 AM – 9:00 AM ET
    Session 9: The Primacy of Front-Line Checkpoint Inhibitors in NSCLC
  • 9:00 AM – 9:07 AM ET
    Session 10: Debate: How to Handle PD-L1 <1% - Chemo + IO
  • 9:07 AM – 9:14 AM ET
    Session 10: Debate: How to Handle PD-L1 <1% - IO Combos
  • 9:14 AM – 9:21 AM ET
    Session 10: Debate: How to Handle PD-L1 1-49% - Chemo + IO
  • 9:21 AM – 9:28 AM ET
    Session 10: Debate: How to Handle PD-L1 1-49% - IO Only
  • 9:28 AM – 9:45 AM ET
    Session 10: Debates: How to Handle PD-L1
  • 9:45 AM – 9:50 AM ET
    Exhibit Hall
  • 9:50 AM – 10:50 AM ET
    Non-CME Innovation Theater
  • 10:50 AM – 11:00 AM ET
    Exhibit Hall
  • 11:00 AM – 11:45 AM ET
    Session 11: Fusions as a Target in Lung Cancer: RET, NTRK, NRG1, ROS1
  • 11:45 AM – 12:30 PM ET
    Session 12: Updates from Recent Meetings
  • 12:30 PM – 1:35 PM ET
    Lunch Break
  • 1:35 PM – 1:42 PM ET
    Debate: How to Handle PD-L1 >50% - Chemo + IO
  • 1:42 PM – 1:49 PM ET
    Debate: How to Handle PD-L1 >50% - IO Only

    Presenter: Jamie E. Chaft, MD – Memorial Sloan Kettering Cancer Center

  • 1:49 PM – 1:56 PM ET
    Debate: Neoadjuvant vs Adjuvant Therapy - Neoadjuvant

    Presenter: Jamie E. Chaft, MD – Memorial Sloan Kettering Cancer Center

  • 1:56 PM – 2:03 PM ET
    Debate: Neoadjuvant vs Adjuvant Therapy - Adjuvant
  • 2:03 PM – 2:20 PM ET
    Session 13: Debates: How to Handle PD-L1 and Neoadjuvant vs Adjuvant

    Panelist: Patrick Forde, MD – Johns Hopkins University

    Panelist: Jamie E. Chaft, MD – Memorial Sloan Kettering Cancer Center

  • 2:20 PM – 3:05 PM ET
    Session 14: Targeted Therapy for MET-Dependent Lung Cancers: Have We Met Our Match?
  • 3:05 PM – 3:35 PM ET
    Exhibit Hall
  • 3:35 PM – 4:20 PM ET
    Session 15: KRAS Mutations: Taming a "Defiant" Oncogene in NSCLC
  • 4:20 PM – 5:05 PM ET
    Session 16: BRAF Mutations: Identifying and Addressing a Rare Oncogenic Driver

    Invited Speaker: Lyudmila Bazhenova, MD – University of California, San Diego

  • Saturday, September 23, 2023
  • 8:00 AM – 8:15 AM ET
    Welcome
  • 8:15 AM – 9:00 AM ET
    Session 17: The Road from DNA to Protein: Navigating the Minefield of Expression Amplification and Mutation
  • 9:00 AM – 9:45 AM ET
    Session 18: The Power of Patient Advocacy
  • 9:45 AM – 10:05 AM ET
    Break
  • 10:05 AM – 10:50 AM ET
    Session 19: Serial Monitoring Using Liquid Biopsy

    Presenter: Christian Rolfo

  • 10:50 AM – 11:35 AM ET
    Session 20: Understanding Lambert-Eaton Myasthenic Syndrome and Its Association with Small Cell Lung Cancer
  • 11:35 AM – 12:20 PM ET
    Lunch Break
  • 12:20 PM – 1:05 PM ET
    Session 21: Finally Moving Forward in SCLC: The Pace of Progress is No Longer Glacial
  • 1:05 PM – 1:15 PM ET
    Exhibit Hall
  • 1:15 PM – 1:30 PM ET
    Session 22: Debate: Prophylactic Cranial Irradiation (PCI) in SCLC - Yes

    Debate Speaker: Charles Simone

  • 1:30 PM – 1:45 PM ET
    Session 22: Debate: Prophylactic Cranial Irradiation (PCI) in SCLC - No
  • 1:45 PM – 2:00 PM ET
    Session 22: Debate: Prophylactic Cranial Irradiation (PCI) in SCLC

    Panelist: Daniel Gomez, MD – Memorial Sloan Kettering Cancer Center

    Panelist: Charles Simone

  • 2:00 PM – 2:45 PM ET
    Session 23: How to Handle PS2 Patients and the Elderly